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BACKGROUND: Transfusion-associated graft-versus-
host disease (TA-GVHD) is a rare complication of trans-
fusion of nonirradiated blood components. It usually
affects children in high-risk groups, including those who
have primary immunodeficiencies (PIDs). It usually pre-
sents with skin, hepatic, digestive, and hematologic
involvement and is normally fatal.
CASE REPORT: We report the case of a nonlethal,
attenuated, TA-GVHD in a 7-month-old boy. The
disease was marked by the presence of a severe
rash but lacked all the other usual manifestations. We
speculate that the unusually benign course of this
disease, which has normally a fulminant course,
was due to the fact that this child was under high-dose
corticotherapy at the time of the engraftment. This
fortunate coincidence led to the survival of this
child and allowed the diagnosis of a combined
immunodeficiency.
CONCLUSION: A high index of suspicion is required for
the diagnosis and proper management of PID. The
administration of nonirradiated blood components in
the first year of life, sometimes before the clinical
suspicion of a PID, is of great concern. TA-GVHD
may be more prevalent than reported in the literature
and it is possibly a nonidentified cause of death in
recipients with unexplained death and nondiagnosed
PID.
T
ransfusion-associated graft-versus-host disease
(TA-GVHD) is a rare complication of blood
transfusion.1 Its true incidence is not known but
it is estimated that it is decreasing with the
routine application of the prevention techniques, such as
the gamma irradiation of cellular blood products with
doses of 25 to 50 Gy for transfusions in recipients belong-
ing to risk groups2 and leukoreduction (with much better
performance with the recent advances of the filtration
technology) of all blood components.3 The “threshold”
dose of lymphocytes required for TA-GVHD in humans is
not known andprobably depends on the recipient’s ability
to reject the transfused lymphocytes.1 As little as 3 ¥ 104 T
lymphocytes is sufficient to cause lethal TA-GVHD in
marrow transplant recipients.4 It has been stated that
gamma irradiation with 25 Gy is adequate to cause T-cell
depletion and prevent T-cell growth.5
No cases of TA-GVHD were reported in 2008 in the
United Kingdom and there was only one report since the
implementation of leukoreduction of all blood compo-
nents (except granulocytes) in 1999.6 Nevertheless,
TA-GVHD might still be underreported7 because it can
mimic many other conditions, such as viral infections or
drug reaction, and it has normally a fulminant course,8
thus not permitting a proper diagnosis. Adding to this, the
current understanding is that there is growing evidence
that supports the possibility of the occurrence of
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subclinical TA-GVHD, especially among small children
and among those who receive cellular transfusions after
traumatic injury.9
In order that TA-GVHD becomes a reality, as
described by Billingham in 1966,10 several conditionsmust
be observed: 1) immunologic competent lymphocytes
must engraft, 2) the hostmust differ antigenically from the
graft, and 3) the recipient must not be able to mount an
adequate response against the graft. Because the first two
premises are almost universally present, the third is the
one that spots the difference and based on it risk groups11
were created for the development ofTA-GVHD (Table 1). A
similar result may be observed when there is a HLA simi-
larity between the donor and the recipient (like in family
member donors or in populations that have a high homo-
geneity inHLA types), even in the absence of immunosup-
pression as the haploidentical donor lymphocytes may
escape the recipient’s immune surveillance and attack the
recipient’s tissues by reacting against HLAs that are not
shared.8 Newborns are at particular risk of TA-GVHD
because they are physiologically immune incompetents
and underlying congenital T-cell immunodeficiencies
may be yet undiagnosed. It is recommended that all blood
for intrauterine transfusions and exchange transfusions
should be irradiated. Interestingly, there is no indication
for the irradiation of blood for routine transfusions of the
term or preterm newborn.1
MATERIALS AND METHODS
Preparation of red blood cells
Using anticoagulant citrate dextrose, the red blood cells
(RBCs) were separated using buffy coat procedure
and stored with saline-adenine-glucose-mannitol
(376 mOsm/L).
DNA polymorphism analysis
Evaluation of chimerism was performed on four
short-tandem repeats locus (HUMTH01, HUMVwA,
HUMF13A1; HUMFES and a sex marker
amelogenin)-specific polymerase chain
reaction (PCR) amplification with dye
primers. Donor and recipient were char-
acterized and the degree of mixture was
evaluated before and after cell separa-
tion using a cell sorter (Aria, BD, Frank-
lin Lakes, NJ). DNA was extracted using
M48 DNA extraction apparatus
(QIAgen, Chatsworth, CA) and short-
tandem repeat amplification was per-
formed in each cell subset using the
primers mentioned. The degree of chi-
merism was analyzed after capillary
array electrophoresis, in an automatic
DNA sequencing machine (Beckman Coulter, Fullerton,
CA), with software (CEQ8000, Beckman Coulter), as
described elsewhere.12
Immunologic testing
Lymphocyte proliferation responses to phytohemaggluti-
nin, concanavalin A, and pokeweedmitogen were assayed
as previously reported.13
Review of the literature
We searched PubMed for articles in English published
between 1980 and August 2009 with the following key
words in the title: “transfusion-associated graft-versus-
host.” We found 151 articles, some descriptions of nonle-
thal cases but no case of attenuated TA-GVHD in a child.
CASE REPORT
A 7-month-old boy with normal development and growth,
as well as no known past infections, was admitted in the
pediatric intensive care unit (PICU) of a tertiary pediatric
hospital in Lisbon for pneumococcal sepsis complicating
an adenovirus bronchiolitis. He needed mechanical ven-
tilation for 7 days. On Days 2 and 7, under 4 mg/kg/day
hydrocortisone, he received two transfusions of 10 mL/kg
leukoreduced, nonirradiated RBCs (aged 0 and 5 days)
from the same donor. On Day 14 he started to have fever
and developed a generalized rash with coalescent
erythematous macules involving palms and soles, treated
as toxic reaction to drugs with 3 mg/kg/day methylpred-
nisolone. All potential drugs involved were discontinued
(namely vancomycin and cefotaxime). The child was dis-
charged to the general pediatrics ward onDay 23where he
stayed until Day 40. His stay in the general pediatrics ward
was marked by severe dependence on oxygen and wors-
ening of the rash, with areas of erythematous papules and
scaling (Fig. 1). On Day 40 he was readmitted in the PICU
for severe rash, sepsis, and respiratory failure. At this time,
TABLE 1. Risk factors for TA-GVHD
Significantly increased risk No risk
Autologous marrow/stem cell transplant recipients Healthy newborns
Allogeneic marrow/stem cell transplant recipients Patients with AIDS
Hodgkin’s disease Acute leukemia without
transplantation
B-cell malignancies (non-Hodgkin’s lymphoma,
multiple myeloma, Waldensrom’s macroglobulinemia,
ALL)
Aplastic anemia
Fludarabine, cladribine therapy
Granulocyte transfusions in infants
Intrauterine transfusions
Directed donations from blood relatives
HLA-matched platelets
Congenital immunodeficiency disorders
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he was under no medication except prednisolone. Viral
PCR and shell viral culture for enterovirus; Epstein-Barr
virus; cytomegalovirus; human herpesvirus 6, 7, and 8;
varicella zoster virus; jc virus; and BK virus were negative.
During this admission, according to the history of severe
infections caused by both virus and bacteria, a clinical
suspicion of combined immunodeficiency (CID) and
GVHD was raised. The immunologic panel confirmed the
hypothesis of a CID/hypomorphe SCID and the most
common genetic defects were ruled out (Table 2).
The child started antibacterial and antifungal pro-
phylaxis, as well as immunoglobulin replacement. Clini-
cally he did very well, apart from two septic events related
with the central venous catheter (Staphylococcus aureus
and Klebsiella pneumoniae).
The chimerism studies confirmed the presence of
exogenous lymphocytes accounting for 16% of total lym-
phocyte count. Maternal engraftment was ruled out and
the lymphocytes were shown to belong to the RBC trans-
fusion donor (Fig. 2). This fact along with the clinical
manifestations (the characteristic rash but lacking diges-
tive, hepatic, and hematologic involvement) and the skin
biopsy (lymphocyte infiltrate with focal parakeratosis and
necrosis of the keratinocytes, without eosinophil infiltra-
tion) led to the diagnosis of attenuated TA-GVHD. Unfor-
tunately, in situ hybridization of the skin biopsy that could
have identified the donor lymphocytes was not per-
formed. He started treatment with cyclosporine (serum
levels of 150-250 ng/mL), allowing the weaning of the cor-
ticotherapy. There was a slow but progressive clinical
improvement with disappearance of the rash along with
the disappearance of the chimerism (1 month after the
beginning of this therapy the chimerism showed the
absence of exogenous lymphocytes). At the age of 14
months he was discharged from the PICU, still under
cyclosporine and corticotherapy without any TA-GVHD
manifestations.
DISCUSSION AND CONCLUSION
TA-GVHD is, as stated above, a fatal complication of blood
transfusion. Its rarity is probably due to the improvement
of the prevention techniques but presumably also to
underdiagnosis.7 The disease usually presents 4 to 21 days
(median, 10 days) after the transfusion of any cellular
blood product and has a fulminant course with skin,
hepatic, digestive, and hematologic involvement.14 The
classic symptoms are fever, rash, liver dysfunction, and
diarrhea. Most commonly, fever is the first manifestation
and it is followed by the appearance of an erythematous,
maculopapular skin rash that starts on the trunk and
spreads through palms and soles. The degree of liver
involvement is variable, as are the gastrointestinal com-
plications. Pancytopenia develops in a median of 16 days
and is severe.
The definitive diagnosis of TA-GVHD needs the dem-
onstration of donor-derived cells or DNA fragments in the
blood or affected tissues of the recipient. Nevertheless, we
underline that the diagnosis of TA-GVHD cannot be based
only in the presence of lymphocytes of the blood transfu-
sion donor as there can exist as much as 1% of subclinical
microchimerism.9
Although it is rare, we speculate that some cases
might be classified as toxic, viral, or autoimmune occur-
rences with fatal outcome in toddlers. In the United
Kingdom 13 cases of TA-GVHD have been reported since
1996with amortality of 100%.6 To our knowledge, no cases
of TA-GVHD have been reported in Portugal since 2000.
Aware of its rarity and knowing the difficulties that
diagnosing this condition raise, the authors believe that
this child had subclinical TA-GVHD. The diagnosis was
based not only on the engraftment of exogenous
Fig. 1. Skin involvement.
TABLE 2. Immunology workup
Laboratory test Result Reference value
Serum immunoglobulins
IgG (mg/mL) 4.64 3.3-6.2
IgM (mg/mL) 0.38 0.2-0.8
IgA (mg/mL) <0.2 0.5-1.3
IgE (U/mL) 17 <30
Vaccine titers
Tetanus (IU/mL) 0.95 >0.15
Diphtheria (IU/mL) 0.12 >0.15
Isohemagglutinin titers A and B <8 >16
Lymphocyte subsets
CD3+ cells/mL 660 2156-3413
CD4+ cells/mL 418 1360-3066
CD4CD45RA (%) 60 75-90
CD8+ cells/mL 231 560-1803
CD19+ cells/mL 385 811-1792
CD16+56+ cells/mL 55 164-801
Lymphocyte proliferation (cpm)
Phytohemagglutinin 3164  511
Concanavalin A 2755  527
Pokeweed mitogen 7890  358
Vb TCR repertoire Normal
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lymphocytes but also on the fact that the recipient was
immunodeficient and had characteristic rash and skin
biopsy,15 and other causes such as viral infections or drug
reaction were ruled out.
The absence of all the other clinical characteristics is
extremely infrequent and is possibly linked to the fact that
he was receiving high-dose corticotherapy for his respira-
tory condition. Its mild course permitted the diagnosis of
a CID. In pediatric practice, apart from the newborn
period and oncology, the most important factor for the
presence of TA-GVHD is primary immunodeficiency
(PID). Among these, the risk is variable and almost exclu-
sive of the cellular PID.1
A high index of suspicion is required for the diagnosis
and proper management of PID. The administration of
nonirradiated blood components in the first year of life,
sometimes before the clinical suspicion of a PID, is of great
concern. TA-GVHD is probably more prevalent than
reported in the literature and it is possibly a nonidentified
cause of death in recipients with unexplained death and
nondiagnosed PID.
In countries where the diagnosis of cellular PID (espe-
cially severe CID) is well below expected (in conformity
with the expected occurrence), the possibility of a fatal
outcome due to the transfusion of nonirradiated blood
components before the suspicion of cellular PID is a
reality. Some institutions have therefore decided to irradi-
ate all blood that is transfused in the first year of life.
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